Bronchiolitis Obliterans Syndrome Complicating Lung or Heart-Lung Transplantation

John A. Belperio; Kathleen Lake; Henry Tazelaar; Michael P. Keane; Robert M. Strieter; Joseph P. Lynch III

doi:10.1055/s-2004-815601

Seminars in Respiratory and Critical Care Medicine, Table of Contents

Semin Respir Crit Care Med 2003; 24(5): 499-530
DOI: 10.1055/s-2004-815601

Bronchiolitis Obliterans Syndrome Complicating Lung or Heart-Lung Transplantation

John A. Belperio¹ , Kathleen Lake² , Henry Tazelaar³ , Michael P. Keane¹ , Robert M. Strieter¹ , Joseph P. Lynch, III¹

¹Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, California
²Department of Medicine, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, Michigan
³Department of Pathology, Mayo Clinic, Rochester, Minnesota

Abstract

ABSTRACT

Lung transplantation is a therapeutic option for patients with end stage lung diseases, but long-term survival remains poor, primarily due to chronic allograft rejection. Bronchiolitis obliterans (BO), a fibrotic process resulting in progressive narrowing of bronchiolar lumens and airflow obstruction, is a manifestation of chronic allograft rejection. The term obliterative bronchiolitis (OB) is synonymous. Once bronchiolitis obliterans syndrome (BOS) develops, progressive decline in pulmonary function is typical; most patients die of respiratory failure within 5 years of onset. The diagnosis of BOS is usually made by clinical, physiological, and radiographic parameters. The dominant risk factor for BOS is acute allograft rejection, but additional factors play contributory roles [e.g., infections; human leukocyte antigen (HLA) mismatching; and injury to the allograft or airways]. The pathogenesis of BOS is complex and involves myriad cell types (both immune and nonimmune) and release of diverse cytokines and chemokines. Unfortunately, current therapies for BOS are of unproven value. A greater understanding of the pathogenic mechanisms operative in BOS are critical to developing novel strategies to treat and prevent this devastating complication.

KEYWORDS

Lung transplantation - allograft rejection - chemokine - cytokines - allorecognition - obliterative bronchiolitis - bronchiolitis obliterans syndrome

Full Text

References

REFERENCES

1 Trulock E P. Lung transplantation. Am J Respir Crit Care Med . 1997; 155 789-818
2 Arcasoy S M, Kotloff R M. Lung transplantation. N Engl J Med . 1999; 340 1081-1091
3 Trulock E. Lung and heart-lung transplantation: overview of results. Semin Respir Crit Care Med . 2001; 22 479-487
4 Hertz M I, Taylor D O, Trulock E P. et al . The registry of the international society for heart and lung transplantation: nineteenth official report-2002. J Heart Lung Transplant . 2002; 21 950-970
5 Estenne M, Hertz M I. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med . 2002; 166 440-444
6 Sharples L D, McNeil K, Stewart S. et al . Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant . 2002; 21 271-281
7 Yousem S A, Duncan S R, Griffith B P. Interstitial and airspace granulation tissue reactions in lung transplant recipients. Am J Surg Pathol . 1992; 16 877-884
8 Luckraz H, Sharples L, McNeil K. et al . Cytomegalovirus antibody status of donor/recipient does not influence the incidence of bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant . 2003; 22 287-291
9 Heng D, Sharples L D, McNeil K. et al . Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant . 1998; 17 1255-1263
10 Chaparro C, Chamberlain D, Maurer J. et al . Bronchiolitis obliterans organizing pneumonia (BOOP) in lung transplant recipients. Chest . 1996; 110 1150-1154
11 Estenne M, Maurer J R, Boehler A. et al . Bronchiolitis obliterans syndrome 2001; an update of the diagnostic criteria. J Heart Lung Transplant . 2002; 21 297-310
12 Kelly K, Hertz M I. Obliterative bronchiolitis. Clin Chest Med . 1997; 18 319-338
13 Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med . 1993; 14 751-763
14 Heng D, Sharples L D, McNeil K. et al . Bronchiolitis obliterans syndrome: incidence, natural history, prognosis, and risk factors. J Heart Lung Transplant . 1998; 17 1255-1263
15 Valentine V G, Robbins R C, Berry G J. et al . Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant . 1996; 15 371-383
16 Verleden G. Chronic allograft rejection (obliterative bronchiolitis). Semin Respir Crit Care Med . 2001; 22 551-557
17 Ouwens J P, van der Mark W T, Koeter G H. et al . Bronchiolar airflow impairment after lung transplantation: an early and common manifestation. J Heart Lung Transplant . 2002; 21 1056-1061
18 Tamm M, Sharples L D, Higenbottam T W. et al . Bronchiolitis obliterans syndrome in heart-lung transplantation: surveillance biopsies. Am J Respir Crit Care Med . 1997; 155 1705-1710
19 Glanville A, Baldwin J, Burke C. et al . Obliterative bronchiolitis after heart-lung transplantation: Apparent arrest by augmented immunosuppression. Ann Intern Med . 1987; 107 300-304
20 Kesten S, Maidenberg A, Winton T. et al . Treatment of presumed and proven acute rejection following six months of lung transplant survival. Am J Respir Crit Care Med . 1995; 152(4 Pt 1) 1321-1324
21 Trulock E P. Management of lung transplant rejection. Chest . 1993; 103 1566-1576
22 Jackson C H, Sharples L D, McNeil K. et al . Acute and chronic onset of bronchiolitis obliterans syndrome (BOS): are they different entities?. J Heart Lung Transplant . 2002; 21 658-666
23 Yousem S A. Lymphocytic bronchitis/bronchiolitis in lung allograft recipients. Am J Surg Pathol . 1993; 17 491-496
24 Yousem S A, Berry G J, Cagle P T. et al . Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant . 1996; 15(1 Pt 1) 1-15
25 Girgis R E, Tu I, Berry G J. et al . Risk factors for the development of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant . 1996; 15 1200-1208
26 El-Gamel A, Sim E, Hasleton P. et al . Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant . 1999; 18 828-837
27 Husain A N, Siddiqui M T, Holmes E W. et al . Analysis of risk factors for the development of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med . 1999; 159 829-833
28 Abernathy E C, Hruban R H, Baumgartner W A. et al . The two forms of bronchiolitis obliterans in heart-lung transplant recipients. Hum Pathol . 1991; 22 1102-1110
29 Milne D S, Gascoigne A D, Ashcroft T. et al . Organizing pneumonia following pulmonary transplantation and the development of obliterative bronchiolitis. Transplantation . 1994; 57 1757-1762
30 Kukafka D S, O'Brien G M, Furukawa S. et al . Surveillance bronchoscopy in lung transplant recipients. Chest . 1997; 111 377-381
31 Valentine V G, Taylor D E, Dhillon G S. et al . Success of lung transplantation without surveillance bronchoscopy. J Heart Lung Transplant . 2002; 21 319-326
32 Patel S R, Kirby T J, McCarthy P M. et al . Lung transplantation: the Cleveland Clinic experience. Cleve Clin J Med . 1993; 60 303-319
33 Hopkins P M, Aboyoun C L, Chhajed P N. et al . Prospective analysis of 1,235 transbronchial lung biopsies in lung transplant recipients. J Heart Lung Transplant . 2002; 21 1062-1067
34 Baz M A, Layish D T, Govert J A. et al . Diagnostic yield of bronchoscopies after isolated lung transplantation. Chest . 1996; 110 84-88
35 Sibley R K, Berry G J, Tazelaar H D. et al . The role of transbronchial biopsies in the management of lung transplant recipients. J Heart Lung Transplant . 1993; 12 308-324
36 Kesten S, Chamberlain D, Maurer J. Yield of surveillance transbronchial biopsies performed beyond two years after lung transplantation. J Heart Lung Transplant . 1996; 15 384-388
37 Boehler A, Vogt P, Zollinger A. et al . Prospective study of the value of transbronchial lung biopsy after lung transplantation. Eur Respir J . 1996; 9 658-662
38 Estenne M, Van Muylem A, Knoop C. et al . Detection of obliterative bronchiolitis after lung transplantation by indexes of ventilation distribution. Am J Respir Crit Care Med . 2000; 162(3 Pt 1) 1047-1051
39 Nathan S D, Ross D J, Belman M J. et al . Bronchiolitis obliterans in single-lung transplant recipients. Chest . 1995; 107 967-972
40 Kramer M R, Stoehr C, Whang J L. et al . The diagnosis of obliterative bronchiolitis after heart-lung and lung transplantation: low yield of transbronchial lung biopsy. J Heart Lung Transplant . 1993; 12 675-681
41 Chamberlain D, Maurer J, Chaparro C. et al . Evaluation of transbronchial lung biopsy specimens in the diagnosis of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant . 1994; 13 963-971
42 Sundaresan S, Trulock E P, Mohanakumar T. et al . Prevalence and outcome of bronchiolitis obliterans syndrome after lung transplantation. Washington University Lung Transplant Group. Ann Thorac Surg . 1995; 60 1341-1347
43 Cooper J D, Billingham M, Egan T. et al . A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant . 1993; 12 713-716
44 Chacon R A, Corris P A, Dark J H. et al . Tests of airway function in detecting and monitoring treatment of obliterative bronchiolitis after lung transplantation. J Heart Lung Transplant . 2000; 19 263-269
45 Patterson G M, Wilson S, Whang J L. et al . Physiologic definitions of obliterative bronchiolitis in heart-lung and double lung transplantation: a comparison of the forced expiratory flow between 25% and 75% of the forced vital capacity and forced expiratory volume in one second. J Heart Lung Transplant . 1996; 15 175-181
46 Reynaud-Gaubert M, Thomas P, Badier M. et al . Early detection of airway involvement in obliterative bronchiolitis after lung transplantation: functional and bronchoalveolar lavage cell findings. Am J Respir Crit Care Med . 2000; 161 1924-1929
47 Martinez J A, Paradis I L, Dauber J H. et al . Spirometry values in stable lung transplant recipients. Am J Respir Crit Care Med . 1997; 155 285-290
48 Nathan S D, Barnett S D, Wohlrab J. et al . Bronchiolitis obliterans syndrome: utility of the new guidelines in single lung transplant recipients. J Heart Lung Transplant . 2003; 22 427-432
49 Morlion B, Knoop C, Paiva M. et al . Internet-based home monitoring of pulmonary function after lung transplantation. Am J Respir Crit Care Med . 2002; 165 694-697
50 Finkelstein S M, Snyder M, Stibbe C E. et al . Staging of bronchiolitis obliterans syndrome using home spirometry. Chest . 1999; 116 120-126
51 Stanbrook M B, Kesten S. Bronchial hyperreactivity after lung transplantation predicts early bronchiolitis obliterans. Am J Respir Crit Care Med . 1999; 160 2034-2039
52 Rajagopalan N, Maurer J, Kesten S. Bronchodilator response at low lung volumes predicts bronchiolitis obliterans in lung transplant recipients. Chest . 1996; 109 405-407
53 Lee E S, Gotway M B, Reddy G P. et al . Early bronchiolitis obliterans following lung transplantation: accuracy of expiratory thin-section CT for diagnosis. Radiology . 2000; 216 472-477
54 Leung A N, Fisher K, Valentine V. et al . Bronchiolitis obliterans after lung transplantation: detection using expiratory HRCT. Chest . 1998; 113 365-370
55 Siegel M J, Bhalla S, Gutierrez F R. et al . Post-lung transplantation bronchiolitis obliterans syndrome: usefulness of expiratory thin-section CT for diagnosis. Radiology . 2001; 220 455-462
56 Bankier A A, Van Muylem A, Knoop C. et al . Bronchiolitis obliterans syndrome in heart-lung transplant recipients: diagnosis with expiratory CT. Radiology . 2001; 218 533-539
57 Medina L S, Siegel M J, Glazer H S. et al . Diagnosis of pulmonary complications associated with lung transplantation in children: value of CT vs histopathologic studies. AJR Am J Roentgenol . 1994; 162 969-974
58 Worthy S A, Park C S, Kim J S. et al . Bronchiolitis obliterans after lung transplantation: high-resolution CT findings in 15 patients. AJR Am J Roentgenol . 1997; 169 673-677
59 Ikonen T, Kivisaari L, Harjula A L. et al . Value of high-resolution computed tomography in routine evaluation of lung transplantation recipients during development of bronchiolitis obliterans syndrome. J Heart Lung Transplant . 1996; 15 587-595
60 Slebos D J, Scholma J, Marike Boezen H. et al . Longitudinal profile of bronchoalveolar lavage cell characteristics in patients with a good outcome after lung transplantation. Am J Respir Crit Care Med . 2002; 165 501-507
61 Zheng L, Walters E H, Ward C. et al . Airway neutrophilia in stable and bronchiolitis obliterans syndrome patients following lung transplantation. Thorax . 2000; 55 53-59
62 DiGiovine B, Lynch III P J, Martinez F J. et al . Bronchoalveolar lavage neutrophilia is associated with obliterative bronchiolitis after lung transplantation: role of IL-8. J Immunol . 1996; 157 4194-4202
63 Reynaud-Gaubert M, Marin V, Thirion X. et al . Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of posttransplant airway obliteration. J Heart Lung Transplant . 2002; 21 721-730
64 Belperio J A, Burdick M D, Keane M P. et al . The role of the CC chemokine, RANTES, in acute lung allograft rejection. J Immunol . 2000; 165 461-472
65 Belperio J A, Keane M P, Burdick M D. et al . Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest . 2001; 108 547-556
66 Belperio J A, DiGiovine B, Keane M P. et al . Interleukin-1 receptor antagonist as a biomarker for bronchiolitis obliterans syndrome in lung transplant recipients. Transplantation . 2002; 73 591-599
67 Belperio J A, Keane M P, Burdick M D. et al . Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol . 2002; 169 1037-1049
68 Scholma J, Slebos D J, Boezen H M. et al . Eosinophilic granulocytes and interleukin-6 level in bronchoalveolar lavage fluid are associated with the development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med . 2000; 162 2221-2225
69 Gabbay E, Walters E H, Orsida B. et al . Post-lung transplant bronchiolitis obliterans syndrome (BOS) is characterized by increased exhaled nitric oxide levels and epithelial inducible nitric oxide synthase. Am J Respir Crit Care Med . 2000; 162 2182-2187
70 Gabbay E, Fisher A J, Small T. et al . Exhaled single-breath nitric oxide measurements are reproducible, repeatable and reflect levels of nitric oxide found in the lower airways. Eur Respir J . 1998; 11 467-472
71 Verleden G M, Dupont L, Lamont J. et al . Is there a role for measuring exhaled nitric oxide in lung transplant recipients with chronic rejection?. J Heart Lung Transplant . 1998; 17 231-232
72 Brugiere O, Pessione F, Thabut G. et al . Bronchiolitis obliterans syndrome after single-lung transplantation: impact of time to onset on functional pattern and survival. Chest . 2002; 121 1883-1889
73 Snell G I, Esmore D S, Williams T J. Cytolytic therapy for the bronchiolitis obliterans syndrome complicating lung transplantation Chest . 1996; 109 874-878
74 Reinsmoen N L, Bolman R M, Savik K. et al . Are multiple immunopathogenetic events occurring during the development of obliterative bronchiolitis and acute rejection?. Transplantation . 1993; 55 1040-1044
75 Kroshus T J, Kshettry V R, Savik K. et al . Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg . 1997; 114 195-202
76 Smith M A, Sundaresan S, Mohanakumar T. et al . Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg . 1998; 116 812-820
77 Bando K, Paradis I L, Komatsu K. et al . Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg . 1995; 109 49-57
78 Keller C A, Cagle P T, Brown R W. et al . Bronchiolitis obliterans in recipients of single, double, and heart-lung transplantation. Chest . 1995; 107 973-980
79 Bando K, Paradis I L, Similo S. et al . Obliterative bronchiolitis after lung and heart-lung transplantation: an analysis of risk factors and management. J Thorac Cardiovasc Surg . 1995; 110 4-14
80 Duncan S R, Paradis I L, Yousem S A. et al . Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis . 1992; 146 1419-1425
81 Speich R, Thurnheer R, Gaspert A. et al . Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation . 1999; 67 315-320
82 Soghikian M V, Valentine V G, Berry G J. et al . Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant . 1996; 15 881-887
83 Duncan S R, Paradis I L, Dauber J H. et al . Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis . 1992; 146(5 Pt 1) 1213-1215
84 Kruger R M, Shannon W D, Arens M Q. et al . The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation. Transplantation . 1999; 68 1272-1279
85 Taylor P M, Rose M L, Yacoub M H. Expression of MHC antigens in normal human lungs and transplanted lungs with obliterative bronchiolitis. Transplantation . 1989; 48 506-510
86 Beck S, Barrell B G. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature . 1988; 331 269-272
87 Arbustini E, Morbini P, Grasso M. et al . Human cytomegalovirus early infection, acute rejection, and major histocompatibility class II expression in transplanted lung: molecular, immunocytochemical, and histopathologic investigations. Transplantation . 1996; 61 418-427
88 Theise N D, Haber M M, Grimes M M. Detection of cytomegalovirus in lung allografts: comparison of histologic and immunohistochemical findings. Am J Clin Pathol . 1991; 96 762-766
89 Opelz G, Mytilineos J, Scherer S. et al . Analysis of HLA-DR matching in DNA-typed cadaver kidney transplants. Transplantation . 1993; 55 782-785
90 Opelz G, Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. The Collaborative Transplant Study. N Engl J Med . 1994; 330 816-819
91 Morris P J. HLA matching and cardiac transplantation. N Engl J Med . 1994; 330 857-858
92 Iwaki Y, Yoshida Y, Griffith B. The HLA matching effect in lung transplantation. Transplantation . 1993; 56 1528-1529
93 Keogh A, Kaan A, Doran T. et al . HLA mismatching and outcome in heart, heart-lung, and single lung transplantation. J Heart Lung Transplant . 1995; 14 444-451
94 Bando K, Paradis I L, Keenan R J. et al . Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. J Heart Lung Transplant . 1995; 14 692-698
95 Harjula A, Baldwin J C, Starnes V A. et al . Proper donor selection for heart-lung transplantation: the Stanford experience. J Thorac Cardiovasc Surg . 1987; 94 874-880
96 Wisser W, Wekerle T, Zlabinger G. et al . Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant . 1996; 15 1209-1216
97 Quantz M A, Bennett L E, Meyer D M. et al . Does human leukocyte antigen matching influence the outcome of lung transplantation?. <~>An analysis of 3,549 lung transplantations. J Heart Lung Transplant . 2000; 19 473-479
98 King R C, Binns O A, Rodriguez F. et al . Reperfusion injury significantly impacts clinical outcome after pulmonary transplantation. Ann Thorac Surg . 2000; 69 1681-1685
99 Sleiman C, Mal H, Fournier M. et al . Pulmonary reimplantation response in single-lung transplantation. Eur Respir J . 1995; 8 5-9
100 Fisher A J, Wardle J, Dark J H. et al . Nonimmune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant . 2002; 21 1206-1212
101 Christie J D, Bavaria J E, Palevsky H I. et al . Primary graft failure following lung transplantation. Chest . 1998; 114 51-60
102 Waddell T K, Gorczynski R M, DeCampos K N. et al . Major histocompatibility complex expression and lung ischemia-reperfusion in rats. Ann Thorac Surg . 1996; 62 866-872
103 Fisher A J, Donnelly S C, Hirani N. et al . Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med . 2001; 163 259-265
104 Fisher A J, Donnelly S C, Hirani N. et al . Enhanced pulmonary inflammation in organ donors following fatal nontraumatic brain injury. Lancet . 1999; 353 1412-1413
105 Takada M, Nadeau K C, Hancock W W. et al . Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation . 1998; 65 1533-1542
106 Clark S C, Sudarshan C, Khanna R. et al . Controlled reperfusion and pentoxifylline modulate reperfusion injury after single lung transplantation. J Thorac Cardiovasc Surg . 1998; 115 1335-1341
107 Fiser S M, Kron I L, Long S M. et al . Influence of graft ischemic time on outcomes following lung transplantation. J Heart Lung Transplant . 2001; 20 1291-1296
108 Novick R J, Bennett L E, Meyer D M. et al . Influence of graft ischemic time and donor age on survival after lung transplantation. J Heart Lung Transplant . 1999; 18 425-431
109 Ueno T, Snell G I, Williams T J. et al . Impact of graft ischemic time on outcomes after bilateral sequential single-lung transplantation. Ann Thorac Surg . 1999; 67 1577-1582
110 Kshettry V R, Kroshus T J, Burdine J. et al . Does donor organ ischemia over four hours affect long-term survival after lung transplantation?. J Heart Lung Transplant . 1996; 15 169-174
111 Gammie J S, Stukus D R, Pham S M. et al . Effect of ischemic time on survival in clinical lung transplantation. Ann Thorac Surg . 1999; 68 2015-2020
112 Snell G I, Rabinov M, Griffiths A. et al . Pulmonary allograft ischemic time: an important predictor of survival after lung transplantation. J Heart Lung Transplant . 1996; 15 160-168
113 Dusmet M, Maurer J, Winton T. et al . Methotrexate can halt the progression of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant . 1996; 15 948-954
114 Hosenpud J D, Bennett L E, Keck B M. et al . Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease Lancet . 1997; 351(9095) 24-27
115 Glanville A R, Marshman D, Keogh A. et al . Outcome in paired recipients of single lung transplants from the same donor. J Heart Lung Transplant . 1995; 14 878-882
116 Winton T L, Miller J D, deHoyos A. et al . Graft function, airway healing, rejection, and survival in pulmonary transplantation are not affected by graft ischemia in excess of 5 hours. Transplant Proc . 1993; 25(1 Pt 2) 1649-1650
117 Marshall R, Bellingan G, Laurent G. The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax . 1998; 53 815-817
118 Boehler A, Chamberlain D, Kesten S. et al . Lymphocytic airway infiltration as a precursor to fibrous obliteration in a rat model of bronchiolitis obliterans. Transplantation . 1997; 64 311-317
119 Hohlfeld J, Niedermeyer J, Hamm H. et al . Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant . 1996; 15 888-894
120 Billings J L, Hertz M I, Savik K. et al . Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant . 2002; 21 559-566
121 Winter J B, Gouw A SH, Groen M. et al . Respiratory viral infections aggravate airway damage caused by chronic rejection in rat lung allografts. Transplantation . 1994; 57 418-422
122 Norgaard M A, Andersen C B, Pettersson G. Does bronchial artery revascularization influence results concerning bronchiolitis obliterans syndrome and/or obliterative bronchiolitis after lung transplantation?. Eur J Cardiothorac Surg . 1998; 14 311-318
123 Haider Y, Yonan N, Mogulkoc N. et al . Bronchiolitis obliterans syndrome in single lung transplant recipients: patients with emphysema versus patients with idiopathic pulmonary fibrosis. J Heart Lung Transplant . 2002; 21 327-333
124 Sundaresan S, Mohanakumar T, Smith M A. et al . HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation . 1998; 65 648-653
125 Wiebe K, Harringer W, Wahlers T. et al . ATG induction therapy and the incidence of bronchiolitis obliterans after lung transplantation: does it make a difference?. Transplant Proc . 1998; 30 1517-1518
126 Halloran P F, Homik J, Goes N. et al . The “injury response”: a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc . 1997; 29 79-81
127 Neuringer I P, Mannon R B, Coffman T M. et al . Immune cells in a mouse airway model of obliterative bronchiolitis. Am J Respir Cell Mol Biol . 1998; 19 379-386
128 Holland V A, Cagle P T, Windsor N T. et al . Lymphocyte subset populations in bronchiolitis obliterans after heart-lung transplantation. Transplantation . 1990; 50 955-959
129 Ross D J, Marchevsky A, Kramer M. et al . “Refractoriness” of airflow obstruction associated with isolated lymphocytic bronchiolitis/bronchitis in pulmonary allografts. J Heart Lung Transplant . 1997; 16 832-838
130 Boehler A, Bai X H, Liu M. et al . Upregulation of T-helper 1 cytokines and chemokine expression in post-transplant airway obliteration. Am J Respir Crit Care Med . 1999; 159 1910-1917
131 Magnan A, Mege J L, Escallier J C. et al . Balance between alveolar macrophage IL-6 and TGF-beta in lung-transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med . 1996; 153(4 Pt 1) 1431-1436
132 Magnan A, Mege J L, Reynaud M. et al . Monitoring of alveolar macrophage production of tumor necrosis factor-alpha and interleukin-6 in lung transplant recipients. Marseille and Montreal Lung Transplantation Group. Am J Respir Crit Care Med . 1994; 150 684-689
133 Riise G C, Andersson B A, Kjellstrom C. et al . Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J . 1999; 14 1123-1130
134 Riise G C, Andersson B A, Kjellstrom C. et al . Persistent high BAL fluid granulocyte activation marker levels as early indicators of bronchiolitis obliterans after lung transplant. Eur Respir J . 1999; 14 1123-1130
135 Borger P, Kauffman H F, Scholma J. et al . Human allogeneic CD2+ lymphocytes activate airway-derived epithelial cells to produce interleukin-6 and interleukin-8: possible role for the epithelium in chronic allograft rejection. J Heart Lung Transplant . 2002; 21 567-575
136 Mason N A, Springall D R, Pomerance A. et al . Expression of inducible nitric oxide synthase and formation of peroxynitrite in posttransplant obliterative bronchiolitis. J Heart Lung Transplant . 1998; 17 710-714
137 Mauck K A, Hosenpud J D. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung transplantation. J Heart Lung Transplant . 1996; 15 709-714
138 Hertz M I, Henke C A, Nakhleh R E. et al . Obliterative bronchiolitis after lung transplantation: a fibroproliferative disorder associated with platelet-derived growth factor. Proc Natl Acad Sci USA . 1992; 89 10385-10389
139 Romanska H M, Ikonen T S, Bishop A E. et al . Up-regulation of inducible nitric oxide synthase in fibroblasts parallels the onset and progression of fibrosis in an experimental model of posttransplant obliterative airway disease. J Pathol . 2000; 191 71-77
140 Jonosono M, Fang K C, Keith F M. et al . Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients. J Heart Lung Transplant . 1999; 18 972-985
141 Borger P, Kauffman H F, Timmerman J A. et al . Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells. Transplantation . 2000; 69 1408-1413
142 Klein J, Sato A. The HLA system. First of two parts. N Engl J Med . 2000; 343 702-709
143 Klein J, Sato A. The HLA system. Second of two parts. N Engl J Med . 2000; 343 782-786
144 Rogers N J, Lechler R I. Allorecognition. Am J Transplant . 2001; 1 97-102
145 Benichou G. Direct and indirect antigen recognition: the pathways to allograft immune rejection. Front Biosci . 1999; 4 D476-D480
146 Womer K L, Lee R S, Madsen J C. et al . Tolerance and chronic rejection. Philos Trans R Soc Lond B Biol Sci . 2001; 356 727-738
147 Womer K L, Sayegh M H, Auchincloss Jr H. Involvement of the direct and indirect pathways of allorecognition in tolerance induction. Philos Trans R Soc Lond B Biol Sci . 2001; 356 639-647
148 Parham P, Clayberger C, Zorn S L. et al . Inhibition of alloreactive cytotoxic T lymphocytes by peptides from the alpha 2 domain of HLA-A2. Nature . 1987; 325 625-628
149 Chicz R M, Urban R G, Lane W S. et al . Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature . 1992; 358 764-768
150 Shoskes D A, Wood K J. Indirect presentation of MHC antigens in transplantation. Immunol Today . 1994; 15 32-38
151 Lechler R I, Lombardi G, Batchelor J R. et al . The molecular basis of alloreactivity. Immunol Today . 1990; 11 83-88
152 Sayegh M H, Turka L A. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med . 1998; 338 1813-1821
153 Hayry P, von Willebrand E, Parthenais E. et al . The inflammatory mechanisms of allograft rejection. Immunol Rev . 1984; 77 85-142
154 Liu Z, Braunstein N S, Suciu-Foca N. T cell recognition of allopeptides in context of syngeneic MHC. J Immunol . 1992; 148 35-40
155 Valujskikh A, Matesic D, Gilliam A. et al . T cells reactive to a single immunodominant self-restricted allopeptide induce skin graft rejection in mice. J Clin Invest . 1998; 101 1398-1407
156 Fangmann J, Dalchau R, Sawyer G J. et al . T cell recognition of donor major histocompatibility complex class I peptides during allograft rejection. Eur J Immunol . 1992; 22 1525-1530
157 Benichou G, Takizawa P A, Olson C A. et al . Donor major histocompatibility complex (MHC) peptides are presented by recipient MHC molecules during graft rejection. J Exp Med . 1992; 175 305-308
158 Lo D, Burkly L C, Flavell R A. et al . Tolerance in transgenic mice expressing class II major histocompatibility complex on pancreatic acinar cells. J Exp Med . 1989; 170 87-104
159 Ciubotariu R, Liu Z, Colovai A I. et al . Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest . 1998; 101 398-405
160 Vella J P, Spadafora-Ferreira M, Murphy B. et al . Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation . 1997; 64 795-800
161 Gimmi C D, Freeman G J, Gribben J G. et al . Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc Natl Acad Sci USA . 1993; 90 6586-6590
162 Noel P J, Boise L H, Green J M. et al . CD28 costimulation prevents cell death during primary T cell activation. J Immunol . 1996; 157 636-642
163 June C H, Bluestone J A, Nadler L M. et al . The B7 and CD28 receptor families. Immunol Today . 1994; 15 321-331
164 Walunas T L, Bakker C Y, Bluestone J A. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med . 1996; 183 2541-2550
165 Guo Y, Wu Y, Shinde S. et al . Identification of a costimulatory molecule rapidly induced by CD40L as CD44H. J Exp Med . 1996; 184 955-961
166 Rumbley C A, Silver S J, Phillips S M. Dependence of murine obstructive airway disease on CD40 ligand. Transplantation . 2001; 72 1616-1625
167 Tikkanen J M, Lemstrom K B, Koskinen P K. Blockade of CD28/B7-2 costimulation inhibits experimental obliterative bronchiolitis in rat tracheal allografts: suppression of helper T cell type1-dominated immune response. Am J Respir Crit Care Med . 2002; 165 724-729
168 Dinarello C A. Biologic basis for interleukin-1 in disease. Blood . 1996; 87 2095-2147
169 Hu S, Chao C C, Ehrlich L C. et al . Inhibition of microglial cell RANTES production by IL-10 and TGF-beta. J Leukoc Biol . 1999; 65 815-821
170 Bejarano M T, de Waal Malefyt R, Abrams J S. et al . Interleukin-10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. Int Immunol . 1992; 4 1389-1397
171 Lowry R P, Konieczny B, Alexander D. et al . Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice. Transplant Proc . 1995; 27 392-394
172 Boehler A, Chamberlain D, Xing Z. et al . Adenovirus-mediated interleukin-10 gene transfer inhibits post-transplant fibrous airway obliteration in an animal model of bronchiolitis obliterans. Hum Gene Ther . 1998; 9 541-551
173 Raisanen-Sokolowski A, Mottram P L, Glysing-Jensen T. et al . Heart transplants in interferon-gamma, interleukin 4, and interleukin 10 knockout mice: recipient environment alters graft rejection. J Clin Invest . 1997; 100 2449-2456
174 Penttinen R P, Kobayashi S, Bornstein P. Transforming growth factor beta increases mRNA for matrix proteins both in the presence and in the absence of changes in mRNA stability. Proc Natl Acad Sci USA . 1988; 85 1105-1108
175 Roberts A B, Sporn M B, Assoian R K. et al . Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA . 1986; 83 4167-4171
176 Elssner A, Jaumann F, Dobmann S. et al . Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation . 2000; 70 362-367
177 Liu M, Suga M, Maclean A A. et al . Soluble transforming growth factor-beta type III receptor gene transfection inhibits fibrous airway obliteration in a rat model of bronchiolitis obliterans. Am J Respir Crit Care Med . 2002; 165 419-423
178 Beutler B A. The role of tumor necrosis factor in health and disease. J Rheumatol . 1999; 26 (suppl 57) S16-S21
179 Ostensen M E, Thiele D L, Lipsky P E. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol . 1987; 138 4185-4191
180 Piguet P F, Collart M A, Grau G E. et al . Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med . 1989; 170 655-663
181 He Y, Liu W. The preliminary research on the relationship between TNF- and egg-induced granuloma and hepatic fibrosis of schistosomiasis japonica. J Tongji Med Univ . 1996; 16 205-208
182 Hayashi M, Martinez O M, Garcia-Kennedy R. et al . Expression of cytokines and immune mediators during chronic liver allograft rejection. Transplantation . 1995; 60 1533-1538
183 Noronha I L, Eberlein-Gonska M, Hartley B. et al . In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation . 1992; 54 1017-1024
184 Aris R M, Walsh S, Chalermskulrat W. et al . Growth factor upregulation during obliterative bronchiolitis in the mouse model. Am J Respir Crit Care Med . 2002; 166 417-422
185 Smith C R, Jaramillo A, Lu K C. et al . Prevention of obliterative airway disease in HLA-A2-transgenic tracheal allografts by neutralization of tumor necrosis factor. Transplantation . 2001; 72 1512-1518
186 Cambrey A D, Kwon O J, Gray A J. et al . Insulin-like growth factor I is a major fibroblast mitogen produced by primary cultures of human airway epithelial cells. Clin Sci (Lond) . 1995; 89 611-617
187 Goldstein R H, Poliks C F, Pilch P F. et al . Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology . 1989; 124 964-970
188 Rom W N, Basset P, Fells G A. et al . Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest . 1988; 82 1685-1693
189 Homma S, Nagaoka I, Abe H. et al . Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med . 1995; 152(6 Pt 1) 2084-2089
190 Jones J I, Clemmons D R. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev . 1995; 16 3-34
191 Charpin J M, Stern M, Grenet D. et al . Insulinlike growth factor-1 in lung transplants with obliterative bronchiolitis. Am J Respir Crit Care Med . 2000; 161 1991-1998
192 Ross R, Raines E W, Bowen-Pope D F. The biology of platelet-derived growth factor. Cell . 1986; 46 155-169
193 Williams L T. Signal transduction by the platelet-derived growth factor receptor. Science . 1989; 243 1564-1570
194 Heldin C H, Westermark B. Platelet-derived growth factor: three isoforms and two receptor types. Trends Genet . 1989; 5 108-111
195 Kallio E A, Koskinen P K, Aavik E. et al . Role of platelet-derived growth factor in obliterative bronchiolitis (chronic rejection) in the rat. Am J Respir Crit Care Med . 1999; 160 1324-1332
196 Rollins B J. Chemokines. Blood . 1997; 90 909-928
197 Luster A D. Review articles: mechanisms of disease: chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med . 1998; 338 436-445
198 Strieter R M, Kunkel S L. Chemokines and the lung. In: Crystal R, West J, Weibel E, et al, eds. Lung: Scientific Foundations 2nd ed. New York: Raven 1997: 155-186
199 Riise G C, Williams A, Kjellstrom C. et al . Bronchiolitis obliterans syndrome in lung transplant recipients is associated with increased neutrophil activity and decreased antioxidant status in the lung. Eur Respir J . 1998; 12 82-88
200 Elssner A, Jaumann F, Dobmann S. et al . Elevated levels of interleukin-8 and transforming growth factor-beta in bronchoalveolar lavage fluid from patients with bronchiolitis obliterans syndrome: proinflammatory role of bronchial epithelial cells. Munich Lung Transplant Group. Transplantation . 2000; 70 362-367
201 Elssner A, Vogelmeier C. The role of neutrophils in the pathogenesis of obliterative bronchiolitis after lung transplantation. Transpl Infect Dis . 2001; 3 168-176
202 De Perrot M, Sekine Y, Fischer S. et al . Interleukin-8 release during early reperfusion predicts graft function in human lung transplantation. Am J Respir Crit Care Med . 2002; 165 211-215
203 Uvama T, Winter J B, Groen G. et al . Late airway changes caused by chronic rejection in rat lung allografts. Transplantation . 1992; 54 809-812
204 Uyama T, Sakiyama S, Fukumoto T. et al . Graft-infiltrating cells in rat lung allograft with late airway damage. Transplant Proc . 1995; 27 2118-2119
205 Matsumura Y, Marchevsky A, Zuo X J. et al . Assessment of pathological changes associated with chronic allograft rejection and tolerance in two experimental models of rat lung transplantation. Transplantation . 1995; 59 1509-1517
206 Tazelaar H D, Prop J, Nieuwenhuis P. et al . Airway pathology in the transplanted rat lung. Transplantation . 1988; 45 864-869
207 Hertz M I, Jessurun J, King M B. et al . Reproduction of the obliterative bronchiolitis lesion after heterotopic transplantation of mouse airways. Am J Pathol . 1993; 142 1945-1951
208 Suga M, Maclean A A, Keshavjee S. et al . RANTES plays an important role in the evolution of allograft transplant-induced fibrous airway obliteration. Am J Respir Crit Care Med . 2000; 162 1940-1948
209 Gao W, Topham P S, King J A. et al . Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest . 2000; 105 35-44
210 Carr M W, Roth S J, Luther E. et al . Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA . 1994; 91 3652-3656
211 Taub D D, Proost P, Murphy W J. et al . Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest . 1995; 95 1370-1376
212 Charo I F, Myers S J, Herman A. et al . Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA . 1994; 91 2752-2756
213 Agostini C, Calabrese F, Rea F. et al . Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol . 2001; 158 1703-1711
214 Fischereder M, Luckow B, Hocher B. et al . CC chemokine receptor 5 and renal-transplant survival. Lancet . 2001; 357 1758-1761
215 Martinson J J, Chapman N H, Rees D C. et al . Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet . 1997; 16 100-103
216 Libert F, Cochaux P, Beckman G. et al . The deltaccr5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in northeastern Europe. Hum Mol Genet . 1998; 7 399-406
217 Stephens J C, Reich D E, Goldstein D B. et al . Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet . 1998; 62 1507-1515
218 Glanville A, Corris T, McNeil K D. Mycophenolate mofetil (MMF) vs azathioprine (AZA) in lung transplantation for the prevention of bronchiolitis obliterans syndrome (BOS): results of a 3-year international, randomised trial. J Heart Lung Transplant . 2003; 22(S1) P207
219 Glanville A R, Baldwin J C, Burke C M. et al . Obliterative bronchiolitis after heart-lung transplantation: apparent arrest by augmented immunosuppression. Ann Intern Med . 1987; 107 300-304
220 Kesten S, Chaparro C, Scavuzzo M. et al . Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant . 1997; 16 905-912
221 Lynch III P J, McCune W J. Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders. Am J Respir Crit Care Med . 1997; 155 395-420
222 Allen M D, Burke C M, McGregor C G. et al . Steroid-responsive bronchiolitis after human heart-lung transplantation. J Thorac Cardiovasc Surg . 1986; 92(3 Pt 1) 449-451
223 Verleden G M. Bronchiolitis obliterans syndrome after lung transplantation: medical treatment. Monaldi Arch Chest Dis . 2000; 55 140-145
224 Kesten S, Maidenberg A, Winton T. et al . Treatment of presumed and proven acute rejection following six months of lung transplant survival. Am J Respir Crit Care Med . 1995; 152(4 Pt 1) 1321-1324
225 Shapiro R. Tacrolimus in solid organ transplantation: an update. Transplant Proc . 1999; 31 2203-2205
226 Lake K D. Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection. Semin Respir Crit Care Med . 2001; 22 559-580
227 Pirsch J D, Miller J, Deierhoi M H. et al . A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation . 1997; 63 977-983
228 Bismuth H. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicentre Liver Study Group. Transplant Proc . 1995; 27 45-49
229 Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet . 1994; 344 423-428
230 Meiser B M, Uberfuhr P, Fuchs A. et al . Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant . 1998; 17 782-788
231 Reichart B, Meiser B, Vigano M. et al . European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results. European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant . 1998; 17 775-781
232 Pham S M, Kormos R L, Hattler B G. et al . A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg . 1996; 111 764-772
233 Taylor D O, Barr M L, Radovancevic B. et al . A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant . 1999; 18 336-345
234 Jang H J, Kim S C, Han D J. Tacrolimus for rescue therapy in refractory renal allograft rejection. Transplant Proc . 2000; 32 1765-1766
235 Reyes J, Jain A, Mazariegos G. et al . Long-term results after conversion from cyclosporine to tacrolimus in pediatric liver transplantation for acute and chronic rejection. Transplantation . 2000; 69 2573-2580
236 Yamani M H, Starling R C, Pelegrin D. et al . Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant . 2000; 19 337-342
237 Reichenspurner H, Kur F, Treede H. et al . Tacrolimus-based immunosuppressive protocols in lung transplantation. Transplantation Proceedings . 1999; 31 171-172
238 Keenan R J, Konishi H, Kawai A. et al . Clinical trial of tacrolimus versus cyclosporine in lung transplantation [see comments]. Annals of Thoracic Surgery . 1995; 60 580-585
239 Treede H, Kepetko W, Reichenspurner H. et al . Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols. J Heart Lung Transplant . 2001; 20 511-517
240 Zuckermann A, Reichenspurner H, Jaksch P. et al . Long-term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation. J Heart Lung Transplant . 2003; 22(1S) S76-S77
241 Reichenspurner H, Glanville A, Klepetko W. et al . Prospective randomized international, multicenter investigator driven study comparing TAC and CSA (==MMF/steroids) after lung transplantation: interim analysis of 110 patients. J Heart Lung Transplant . 2003; 22(1S) S77
242 Knoop C, Antoine M, Vachiery J L. et al . FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. Transplant Proc . 1994; 26 3240-3241
243 Wiebe K, Harringer W, Franke U. et al . FK506 rescue therapy in lung transplantation. Transplant Proc . 1998; 30 1508-1509
244 Mentzer Jr M R, Jahania M S, Lasley R D. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The US Multicenter FK506 Study Group. Transplantation . 1998; 65 109-113
245 Onsager D R, Canver C C, Jahania M S. et al . Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant . 1999; 18 448-455
246 Horning N R, Lynch J P, Sundaresan S R. et al . Tacrolimus therapy for persistent or recurrent acute rejection after lung transplantation. J Heart Lung Transplant . 1998; 17 761-767
247 Cairn J, Yek T, Banner N R. et al . Time-related changes in pulmonary function after conversion to tacrolimus in bronchiolitis obliterans syndrome. J Heart Lung Transplant . 2003; 22 50-57
248 Ross D J, Lewis M I, Kramer M. et al . FK 506 “rescue” immunosuppression for obliterative bronchiolitis after lung transplantation. Chest . 1997; 112 1175-1179
249 Vitulo P, Oggionni T, Cascina A. et al . Efficacy of tacrolimus rescue therapy in refractory acute rejection after lung transplantation. J Heart Lung Transplant . 2002; 21 435-439
250 Fieguth H G, Krueger S, Wiedenmann D E. et al . Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. Transplant Proc . 2002; 34 1884
251 Kesten S, Chaparro C, Scavuzzo M. et al . Tacrolimus as rescue therapy for bronchiolitis obliterans syndrome. J Heart Lung Transplant . 1997; 16 905-912
252 Lipson D A, Palevsky H I, Kotloff R M. et al . Conversion to tacrolimus (FK506) from cyclosporine after orthotopic lung transplantation. Transplant Proc . 1998; 30 1505-1507
253 Klepetko W, Estenne M, Glanville A. et al . A multicenter study to assess outcome following a switch in the primary immunosuppressant from cyclosporin (CYA) to tacrolimus (TAC) in lung recipients. J Heart Lung Transplant . 2001; 20 208
254 Roman A, Bravo C, Monforte V. et al . Preliminary results of rescue therapy with tacrolimus and mycophenolate mofetil in lung transplanted patients with bronchiolitis obliterans. Transplant Proc . 2002; 34 146-147
255 Sarahrudi K, Carretta A, Wisser W. et al . The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantation. Transpl Int . 2002; 15 24-28
256 Revell M P, Lewis M E, Llewellyn-Jones C G. et al . Conservation of small-airway function by tacrolimus/cyclosporine conversion in the management of bronchiolitis obliterans following lung transplantation. J Heart Lung Transplant . 2000; 19 1219-1223
257 Sollinger H W. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation . 1995; 60 225-232
258 A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation . 1996; 61 1029-1037
259 Kobashigawa J, Miller L, Renlund D. et al . A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators Transplantation . 1998; 66 507-515
260 Ross D J, Waters P F, Levine M. et al . Mycophenolate mofetil versus azathioprine immunosuppressive regimens after lung transplantation: preliminary experience. J Heart Lung Transplant . 1998; 17 768-774
261 Zuckermann A, Klepetko W, Birsan T. et al . Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. J Heart Lung Transplant . 1999; 18 432-440
262 O'Hair D P, Cantu E, McGregor C. et al . Preliminary experience with mycophenolate mofetil used after lung transplantation. J Heart Lung Transplant . 1998; 17 864-868
263 Dunitz J, Hertz M I, Park S J. The risk of bronchiolitis obliterans syndrome is reduced in lung transplant patients who receive mycophenolate mofetil based immunosuppression. J Heart Lung Transplant . 2003; 22(S1) S151
264 Palmer S M, Baz M A, Sanders L. et al . Results of a randomized, prospective, multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation . 2001; 71 1772-1776
265 Bodin L, Grenet D, Gonin F. et al . Cyclosporin C2 monotoring after lung transplantation (LT) in cystic fibrosis (CF) and non CF patients. J Heart Lung Transplant . 2003; 22(S1) P120
266 Kaplan B, Meier-Kriesche H U, Friedman G. et al . The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol . 1999; 39 715-720
267 Shaw L M, Korecka M, van Breeman R. et al . Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem . 1998; 31 323-328
268 Seebacher G, Mallinger R, Laufer G. et al . Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. Adv Exp Med Biol . 1998; 431 801-803
269 Muller M M, Vogl M, Griesmacher A. Mycophenolic acid monitoring in HTX patients: a preliminary report. Therapie . 1997; 52 341-344
270 Dubrey S W, Holt D W, Banner N. Measurement of mycophenolate mofetil plasma levels after heart transplantation and a potential side effect of high levels. Ther Drug Monit . 1999; 21 325-326
271 Shaw L M, Kaplan B, DeNofrio D. et al . Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit . 2000; 22 14-19
272 Shaw L M, Korecka M, DeNofrio D. et al . Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem . 2001; 34 17-22
273 Ensom M H, Partovi N, Decarie D. et al . Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. Ther Drug Monit . 2002; 24 310-314
274 Partovi N, Ensom M H, Fradet G. et al . Factors influence mycophenolate mofetil drug exposure in thoracic organ transplant recipients. J Heart Lung Transplant . 2003; 22(S1) S121
275 DeNofrio D, Loh E, Kao A. et al . Mycophenolic acid concentration are assocated with cardiac allograft rejection. J Heart Lung Transplant . 2000; 19 1071-1076
276 Meiser B M, Pfeiffer M, Schmidt D. et al . Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant . 1999; 18 143-149
277 Meiser B M, Pfeiffer M, Schmidt D. et al . The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels. Transplant Proc . 1999; 31 84-87
278 Meiser B M, Schmidt D, Pfeiffer M. et al .MMF-dose adjustments based on MPA-trough levels after heart transplantation: difference between high and low dose pharmacokinetics. AST Eighteenth Annual Meeting 1999. S110.
279 Devyatko E, Ploner M, Zuckermann A. et al . Value of mycophenolic acid trough level monitoring after lung transplantation. Transplant Proc . 2002; 34 1881-1883
280 Speich R, Boehler A, Thurnheer R. et al . Salvage therapy with mycophenolate mofetil for lung transplant bronchiolitis obliterans: importance of dosage. Transplantation . 1997; 64 533-535
281 Whyte R I, Rossi S J, Mulligan M S. et al . Mycophenolate mofetil for obliterative bronchiolitis syndrome after lung transplantation. Ann Thorac Surg . 1997; 64 945-948
282 Dupont L J, Delcroix M, Vanhaecke D. et al . Azathioprine/mycophenolate conversions in the managment of bronchiolitis obliterans syndrome (BOS) following (heart-) lung transplantation. J Heart Lung Transplant . 2003; 22(1S) S123
283 Sehgal S N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem . 1998; 31 335-340
284 Poston R S, Billingham M, Hoyt E G. et al . Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model. Circulation . 1999; 100 67-74
285 Viklicky O, Zou H, Muller V. et al . SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts. Transplantation . 2000; 69 497-502
286 Fahrni J A, Berry G J, Morris R E. et al . Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model. Transplantation . 1997; 63 533-537
287 Salminen U S, Maasilta P K, Taskinen E I. et al . Prevention of small airway obliteration in a swine heterotopic lung allograft model. J Heart Lung Transplant . 2000; 19 193-206
288 Cahill B C, Somerville K T, Crompton J A. et al . Early experience with sirolimus in lung transplant recipients with chronic allograft rejection. J Heart Lung Transplant . 2003; 22 169-176
289 Snell G I, Valentine V, Love R. et al . One-year results of an international, ransomized, double-blind study of everolimus vs azathioprine as adjunctive therapy to inhibit the decline of pulmonary function in stable lung or heart/lung transplant recipients. J Heart Lung Transplant . 2003; 22(S1) S207-S208
290 Cooper J D, Patterson G A, Trulock E P. Results of single and bilateral lung transplantation in 131 consecutive recipients. Washington University Lung Transplant Group. J Thorac Cardiovasc Surg . 1994; 107 460-470
291 Paradis I, Yousem S, Griffith B. Airway obstruction and bronchiolitis obliterans after lung transplantation. Clin Chest Med . 1993; 14 751-763
292 A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. Ortho Multicenter Transplant Study Group. N Engl J Med . 1985; 313 337-342
293 Aubock J, Irschick E, Romani N. et al . Rejection, after a slightly prolonged survival time, of Langerhans' cell-free allogeneic cultured epidermis used for wound coverage in humans. Transplantation . 1988; 45 730-737
294 O'Connell J B, Renlund D G, Gay Jr A W. et al . Efficacy of OKT3 retreatment for refractory cardiac allograft rejection. Transplantation . 1989; 47 788-792
295 Ross D J, Jordan S C, Nathan S D. et al . Delayed development of obliterative bronchiolitis syndrome with OKT3 after unilateral lung transplantation: a plea for multicenter immunosuppressive trials Chest . 1996; 109 870-873
296 Shennib H, Massard G, Reynaud M. et al . Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. J Heart Lung Transplant . 1994; 13 514-519
297 Date H, Lynch III P J, Sundaresan S. et al . The impact of cytolytic therapy on bronchiolitis obliterans syndrome. J Heart Lung Transplant . 1998; 17 869-875
298 Kesten S, Rajagopalan N, Maurer J. Cytolytic therapy for the treatment of bronchiolitis obliterans syndrome following lung transplantation. Transplantation . 1996; 61 427-430
299 Nashan B, Light S, Hardie I R. et al . Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation . 1999; 67 110-115
300 Vincenti F, Kirkman R, Light S. et al . Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med . 1998; 338 161-165
301 Beniaminovitz A, Itescu S, Lietz K. et al . Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med . 2000; 342 613-619
302 Berard J L, Velez R L, Freeman R B. et al . A review of interleukin-2 receptor antagonists in solid organ transplantation. Pharmacotherapy . 1999; 19 1127-1137
303 Nashan B, Schwinzer R, Schlitt H J. et al . Immunological effects of the anti-IL-2 receptor monoclonal antibody BT 563 in liver allografted patients. Transpl Immunol . 1995; 3 203-211
304 Brock M V, Borja M C, Ferber L. et al . Induction therapy in lung transplantation: a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab. J Heart Lung Transplant . 2001; 20 1282-1290
305 Garrity Jr R E, Villanueva J, Bhorade S M. et al . Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin-2 receptor antibody. Transplantation . 2001; 71 773-777
306 Marom E M, Choi Y W, Palmer S M. et al . Reperfusion edema after lung transplantation: effect of daclizumab. Radiology . 2001; 221 508-514
307 Shaddy R E, Bullock E A, Tani L Y. et al . Methotrexate therapy in pediatric heart transplantation as treatment of recurrent mild to moderate acute cellular rejection. J Heart Lung Transplant . 1994; 13 1009-1013
308 Bourge R C, Kirklin J K, White-Williams C. et al . Methotrexate pulse therapy in the treatment of recurrent acute heart rejection. J Heart Lung Transplant . 1992; 11 1116-1124
309 Olsen S L, O'Connell J B, Bristow M R. et al . Methotrexate as an adjunct in the treatment of persistent mild cardiac allograft rejection. Transplantation . 1990; 50 773-775
310 Ferraro P, Carrier M, White M. et al . Antithymocyte globulin and methotrexate therapy of severe or persistent cardiac allograft rejection. Ann Thorac Surg . 1995; 60 372-376
311 Michael B, Francos G C, Burke Jr F J. et al . Methotrexate is effective in preventing acute and potentially chronic renal allograft rejection. Transplant Proc . 1994; 26 3046-3047
312 Cahill B C, O'Rourke M K, Strasburg K A. et al . Methotrexate for lung transplant recipients with steroid-resistant acute rejection. J Heart Lung Transplant . 1996; 15 1130-1137
313 Komatsu K, Youm W, Konishi H. et al . Prolonged survival of hamster-to-rat pulmonary xenografts by tacrolimus (FK506) and cyclophosphamide. J Heart Lung Transplant . 1996; 15 722-727
314 Miller L W, Wesp A, Jennison S H. et al . Vascular rejection in heart transplant recipients. J Heart Lung Transplant . 1993; 12 S147-S152
315 Verleden G M, Buyse B, Delcroix M. et al . Cyclophosphamide rescue therapy for chronic rejection after lung transplantation. J Heart Lung Transplant . 1999; 18 1139-1142
316 Evans M A, Schomberg P J, Rodeheffer R J. et al . Total lymphoid irradiation: a novel and successful therapy for resistant cardiac allograft rejection. Mayo Clin Proc . 1992; 67 785-790
317 Frist W H, Winterland A W, Gerhardt E B. et al . Total lymphoid irradiation in heart transplantation: adjunctive treatment for recurrent rejection. Ann Thorac Surg . 1989; 48 863-864
318 Hunt S A, Strober S, Hoppe R T. et al . Total lymphoid irradiation for treatment of intractable cardiac allograft rejection. J Heart Lung Transplant . 1991; 10 211-216
319 Levin B, Bohannon L, Warvariv V. et al . Total lymphoid irradiation (TLI) in the cyclosporine era: use of TLI in resistant cardiac allograft rejection. Transplant Proc . 1989; 21(1 Pt 2) 1793-1795
320 Salter M M, Kirklin J K, Bourge R C. et al . Total lymphoid irradiation in the treatment of early or recurrent heart rejection. J Heart Lung Transplant . 1992; 11 902-911
321 O'Hagan A R, Stillwell P C, Arroliga A. et al . Photopheresis in the treatment of refractory bronchiolitis obliterans complicating lung transplantation. Chest . 1999; 115 1459-1462
322 Diamond D A, Michalski J M, Lynch III P J. et al . Efficacy of total lymphoid irradiation for chronic allograft rejection following bilateral lung transplantation. Int J Radiat Oncol Biol Phys . 1998; 41 795-800
323 Valentine V G, Robbins R C, Wehner J H. et al . Total lymphoid irradiation for refractory acute rejection in heart-lung and lung allografts Chest . 1996; 109 1184-1189
324 Chin C, Hunt S, Robbins R. et al . Long-term follow-up after total lymphoid irradiation in pediatric heart transplant recipients. J Heart Lung Transplant . 2002; 21 667-673
325 Perez M, Edelson R, Laroche L. et al . Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes. J Invest Dermatol . 1989; 92 669-676
326 Edelson R, Berger C, Gasparro F. et al . Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med . 1987; 316 297-303
327 Barr M L, Meiser B M, Eisen H J. et al . Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med . 1998; 339 1744-1751
328 Dall'Amico R, Montini G, Murer L. et al . Benefits of photopheresis in the treatment of heart transplant patients with multiple/refractory rejection. Transplant Proc . 1997; 29 609-611
329 Costanzo-Nordin M R, Hubbell E A, O'Sullivan E J. et al . Successful treatment of heart transplant rejection with photopheresis. Transplantation . 1992; 53 808-815
330 Lehrer M S, Rook A H, Tomaszewski J E. et al . Successful reversal of severe refractory cardiac allograft rejection by photopheresis. J Heart Lung Transplant . 2001; 20 1233-1236
331 Wieland M, Thiede V L, Strauss R G. et al . Treatment of severe cardiac allograft rejection with extracorporeal photochemotherapy. J Clin Apheresis . 1994; 9 171-175
332 Wise B V, King K E, Rook A H. et al . Extracorporeal photopheresis in the treatment of persistent rejection in a pediatric lung transplant recipient. Prog Transplant . 2003; 13 61-64
333 Andreu G, Achkar A, Couetil J P. et al . Extracorporeal photochemotherapy treatment for acute lung rejection episode. J Heart Lung Transplant . 1995; 14 793-796
334 Heshmati F, Guillemain R, Achkar A. et al . Traitement du rejet de greffe d'organe par photochimiotherapie extra-corporelle. Ann Med Interne (Paris) . 1994; 145 312-315
335 Slovis B S, Loyd J E, King Jr E L. Photopheresis for chronic rejection of lung allografts. N Engl J Med . 1995; 332 962
336 Keenan R J, Zeevi A, Iacono A T. et al . Efficacy of inhaled cyclosporine in lung transplant recipients with refractory rejection: correlation of intragraft cytokine gene expression with pulmonary function and histologic characteristics. Surgery . 1995; 118 385-391
337 O'Riordan T G, Iacono A, Keenan R J. et al . Delivery and distribution of aerosolized cyclosporine in lung allograft recipients. Am J Respir Crit Care Med . 1995; 151(2 Pt 1) 516-521
338 Iacono A T, Smaldone G C, Keenan R J. et al . Dose-related reversal of acute lung rejection by aerosolized cyclosporine. Am J Respir Crit Care Med . 1997; 155 1690-1698
339 Keenan R J, Iacono A, Dauber J H. et al . Treatment of refractory acute allograft rejection with aerosolized cyclosporine in lung transplant recipients. J Thorac Cardiovasc Surg . 1997; 113 335-340
340 Corcoran T, Smaldone G C, Dauber J. et al . Aerosol cyclosporine provides dose dependent improvement in lung function after lung transplantation. J Heart Lung Transplant . 2003; 22 (suppl 1) S77
341 De Soyza A, Fisher A J, Small T. et al . Inhaled corticosteroids and the treatment of lymphocytic bronchiolitis following lung transplantation. Am J Respir Crit Care Med . 2001; 164 1209-1212
342 Takao M, Higenbottam T W, Audley T. et al . Effects of inhaled nebulized steroids (budesonide) on acute and chronic lung function in heart-lung transplant patients. Transplant Proc . 1995; 27 1284-1285
343 Whitford H, Walters E H, Levvey B. et al . Addition of inhaled corticosteroids to systemic immunosuppression after lung transplantation: a double-blind, placebo-controlled trial. Transplantation . 2002; 73 1793-1799
344 Rubin B K, Tamaoki J. Macrolide antibiotics as biological response modifiers. Curr Opin Investig Drugs . 2000; 1 169-172
345 Culic O, Erakovic V, Parnham M J. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol . 2001; 429 209-229
346 Kadota J, Sakito O, Kohno S. et al . A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. Am Rev Respir Dis . 1993; 147 153-159
347 Kudoh S, Azuma A, Yamamoto M. et al . Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med . 1998; 157(6 Pt 1) 1829-1832
348 Equi A, Balfour-Lynn I M, Bush A. et al . Long-term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet . 2002; 360 978-984
349 Wolter J, Seeney S, Bell S. et al . Effect of long-term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax . 2002; 57 212-216
350 Gerhardt S G, McDyer J F, Girgis R E. et al . Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. Am J Respir Crit Care Med . 2003; 168 121-125
351 Ward W F, Molteni A, Ts'ao C H. et al . Radiation pneumotoxicity in rats: modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys . 1992; 22 623-625
352 Kobayashi J, Crawford S E, Backer C L. et al . Captopril reduces graft coronary artery disease in a rat heterotopic transplant model. Circulation . 1993; 88(5 Pt 2) II286-II290
353 Crawford S E, Huang L, Hsueh W. et al . Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. J Heart Lung Transplant . 1999; 18 470-477
354 Maclean A A, Liu M, Fischer S. et al . Targeting the angiotensin system in posttransplant airway obliteration: the antifibrotic effect of angiotensin converting enzyme inhibition. Am J Respir Crit Care Med . 2000; 162 310-315
355 Mach F. Immunosuppressive effects of statins. Atheroscler Suppl . 2002; 3 17-20
356 Kobashigawa J A, Katznelson S, Laks H. et al . Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med . 1995; 333 621-627
357 Johnson B A, Iacono A T, Zeevi A. et al . Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med . 2003; 167 1271-1278
358 Wenke K, Meiser B, Thiery J. et al . Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation . 1997; 96 1398-1402
359 Kasiske B L, Heim-Duthoy K L, Singer G G. et al . The effects of lipid-lowering agents on acute renal allograft rejection. Transplantation . 2001; 72 223-227
360 Holdaas H, Jardine A G, Wheeler D C. et al . Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. Kidney Int . 2001; 60 1990-1997
361 Sahu K, Sharma R, Gupta A. et al . Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection. Clin Transplant . 2001; 15 173-175
362 Calne R, Moffatt S D, Friend P J. et al . Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation . 1999; 68 1613-1616
363 Rebello P R, Hale G, Friend P J. et al . Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. Transplantation . 1999; 68 1417-1420
364 Reams B D, Davis R D, Curl J. et al . Treatment of refractory acute rejection in a lung transplant recipient with campath 1H. Transplantation . 2002; 74 903-904